DNER and lymphoma: To further improve the anti-tumor potential of BET inhibitors, various combinations with immune modulators [20], epigenetic drugs [12,21], DNA damage repair inhibitors [22] or antibodies [23] are under pre-clinical and clinical investigation and have revealed pre-clinical efficacy in lymphoma.